RxDoctor Payments Data

Stephanie Fries, MD

Hematology & Oncology · Marinette, WINPI 1154681377

Payments from drug & device makers

$373in general payments, 2019–2025

Across 7 payments — averaging $53.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$119
  • Pharmacyclics LLC, An Abbvie Company$72
  • AstraZeneca$66
  • Johnson & Johnson$65
  • Merck$25
  • AbbVie$14
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$28376%
  • Education$9024%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$373 in reported general payments places this provider in the 30th percentile of 248 hematology & oncology providers in Wisconsin.

See all hematology & oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$90,287
Medicare patients
274
Services billed
782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide41$790,916
PomalystPomalidomide18$436,800
CalquenceAcalabrutinib Maleate31$409,366
ImbruvicaIbrutinib24$405,557
Lenalidomide16$231,247
VenclextaVenetoclax17$198,509
EliquisApixaban218$147,961
Abiraterone Acetate22$36,228
XareltoRivaroxaban29$25,399
Anastrozole183$2,988
Fentanyl19$1,784
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen111$1,601
Acyclovir72$1,142
Prochlorperazine Maleate88$1,009
Hydroxyurea32$920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$66$409,36631 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$72$405,55724 claims
AbbVieVenclexta$14$198,50917 claims
PfizerEliquis$119$147,961218 claims
Johnson & JohnsonXarelto$65$25,39929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 248 hematology & oncology providers in Wisconsin.

Other hematology & oncology in Marinette

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →